Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients & the Healthc...
October 14 2016 - 8:30AM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced the launch of Biosimilars Clarified
(www.merckclarifiesbiosimilars.com), a new educational website for
patients, caregivers and the healthcare community that is designed
to provide clear, concise and straightforward information about
biosimilar medicines.
Biosimilars are a type of biological product that are approved
by the U.S. Food and Drug Administration (FDA) because they are
highly similar to an already FDA-approved biological product, known
as the originator biologic or reference product, and have been
shown to have no clinically meaningful differences in terms of the
safety, purity and potency of the product.
“Biosimilars can offer alternative treatment options, and have
the potential to help reduce healthcare spending and increase
access to important biologic medicines,” said Dora Bibila, general
manager, Merck Biosimilars. “At Merck, we want to provide
educational resources for patients and caregivers to help them get
the information they want and need. We believe the more patients
know, the more they can be in charge of their health – Biosimilars
Clarified is designed to help answer their questions about
biosimilars.”
Biosimilars Clarified offers a host of informative features in a
simple, easy-to-use question-and-answer format. The website was
developed to provide patients, their caregivers, healthcare
professionals and others clarification on such topics as:
- What are biologic medicines?
- Biosimilars – are they safe and
effective?
- The value of biosimilars and increasing
access to treatment.
- The availability of support programs
for patients taking biosimilars.
“Merck is one of the largest pharmaceutical companies in the
world today, and we have a long-standing commitment to supporting
patients and the healthcare community. We are continuing that
commitment with Merck Biosimilars,” Bibila said.
About Merck
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161014005136/en/
MerckRobert Consalvo, 908-236-1127
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024